Literature DB >> 11040940

Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma.

P Mendes-da-Silva1, A Moreira, J Duro-da-Costa, D Matias, C Monteiro.   

Abstract

AIMS: Loss of heterozygosity (LOH) at specific chromosomal regions strongly suggests the existence of tumour suppressor genes at the relevant segment. Frequent LOH on chromosome 5q has been reported in a wide variety of human tumours, including those of the lung. The aim of this study was to screen for LOH and to clarify the location of putative tumour suppressor genes on chromosome 5 implicated in the genesis and/or development of non-small cell lung carcinoma.
METHODS: Thirty three patients with advanced non-small cell lung carcinoma were screened for LOH with a panel of 21 microsatellite DNA markers spanning the entire chromosome 5, using semi-automated fluorochrome based methodology.
RESULTS: Twenty of the non-small cell lung carcinoma samples displayed LOH for one or more informative locus. LOH involving only 5q was found in 10 of 14 of the informative samples. Deletions involving 5p only were not present in the samples under study. There was no evidence of microsatellite instability in any of the analysed loci. These results indicate the presence of five distinct segments displaying high frequencies of deletion on chromosome 5, namely: 5q11.2-q12.2, 5q15 (D5S644 locus), 5q22.3-q23.1, 5q31.1, and 5q35.3. Eight of 14 samples had simultaneous interstitial deletions in at least two different regions. Moreover, concomitant deletion of three and four distinct regions was displayed in three of 14 and two of 14, respectively, of the informative samples.
CONCLUSION: Allelic deletion on chromosome 5 is a frequent event in patients with non-small cell lung carcinoma. These results suggest the involvement of these five regions, either independently or simultaneously, in both lung squamous cell carcinoma and lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040940      PMCID: PMC1186967          DOI: 10.1136/mp.53.4.184

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  23 in total

1.  Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer.

Authors:  D D'Amico; D P Carbone; B E Johnson; S J Meltzer; J D Minna
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

2.  Application of automated DNA sizing technology for genotyping microsatellite loci.

Authors:  J S Ziegle; Y Su; K P Corcoran; L Nie; P E Mayrand; L B Hoff; L J McBride; M N Kronick; S R Diehl
Journal:  Genomics       Date:  1992-12       Impact factor: 5.736

3.  Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated.

Authors:  H Harada; K Willison; J Sakakibara; M Miyamoto; T Fujita; T Taniguchi
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

4.  Chromosome 5 aberrations and genetic predisposition to lung cancer.

Authors:  X Wu; Y Zhao; B L Kemp; C I Amos; M J Siciliano; M R Spitz
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

5.  Association of p53 genomic instability with the glutathione S-transferase null genotype in gastric cancer in the Portuguese population.

Authors:  A R Conde; G Martins; C Saraiva; J Rueff; C Monteiro
Journal:  Mol Pathol       Date:  1999-06

6.  Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer.

Authors:  R C Peralta; A G Casson; R N Wang; S Keshavjee; M Redston; B Bapat
Journal:  Int J Cancer       Date:  1998-11-23       Impact factor: 7.396

7.  Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer.

Authors:  H Nozawa; E Oda; S Ueda; G Tamura; C Maesawa; T Muto; T Taniguchi; N Tanaka
Journal:  Int J Cancer       Date:  1998-08-12       Impact factor: 7.396

8.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.

Authors:  M M Le Beau; R Espinosa; W L Neuman; W Stock; D Roulston; R A Larson; M Keinanen; C A Westbrook
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

9.  Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer.

Authors:  A Achille; A Baron; G Zamboni; C Di Pace; S Orlandini; A Scarpa
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

10.  Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology.

Authors:  L Cawkwell; S M Bell; F A Lewis; M F Dixon; G R Taylor; P Quirke
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more
  17 in total

1.  Allelic loss on chromosome 5q34 is associated with poor prognosis in hepatocellular carcinoma.

Authors:  P Saelee; S Wongkham; V Bhudhisawasdi; B Sripa; S Chariyalertsak; S Petmitr
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

2.  Molecular characterisation of the pericentric inversion that distinguishes human chromosome 5 from the homologous chimpanzee chromosome.

Authors:  Justyna M Szamalek; Violaine Goidts; Nadia Chuzhanova; Horst Hameister; David N Cooper; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

3.  An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.

Authors:  Piia-Riitta Karhemo; Antti Rivinoja; Johan Lundin; Maija Hyvönen; Anastasiya Chernenko; Johanna Lammi; Harri Sihto; Mikael Lundin; Päivi Heikkilä; Heikki Joensuu; Petri Bono; Pirjo Laakkonen
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

4.  BRCTx is a novel, highly conserved RAD18-interacting protein.

Authors:  David J Adams; Louise van der Weyden; Fanni V Gergely; Mark J Arends; Bee Ling Ng; David Tannahill; Roland Kanaar; Andrea Markus; Brian J Morris; Allan Bradley
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

5.  Intracellular localization and domain organization of human TRIM41 proteins.

Authors:  Mayumi Tanaka; Yoshiko Fukuda; Keisuke Mashima; Ryo Hanai
Journal:  Mol Biol Rep       Date:  2005-06       Impact factor: 2.316

6.  Variability in the incidence of miRNAs and genes in fragile sites and the role of repeats and CpG islands in the distribution of genetic material.

Authors:  Alessandro Laganà; Francesco Russo; Catarina Sismeiro; Rosalba Giugno; Alfredo Pulvirenti; Alfredo Ferro
Journal:  PLoS One       Date:  2010-06-17       Impact factor: 3.240

Review 7.  Cancer models, genomic instability and somatic cellular Darwinian evolution.

Authors:  Mark P Little
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

8.  Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Authors:  Paolo Sportoletti; Silvia Grisendi; Samia M Majid; Ke Cheng; John G Clohessy; Agnes Viale; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Blood       Date:  2008-01-22       Impact factor: 22.113

9.  A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Authors:  Chengyin Min; Ziyang Yu; Kathrin H Kirsch; Yingshe Zhao; Siddharth R Vora; Philip C Trackman; Douglas B Spicer; Lynn Rosenberg; Julie R Palmer; Gail E Sonenshein
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

10.  Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Authors:  Ying Ye; Michael A McDevitt; Mingzhou Guo; Wei Zhang; Oliver Galm; Steven D Gore; Judith E Karp; Jaroslaw P Maciejewski; Jeanne Kowalski; Hua-Ling Tsai; Lukasz P Gondek; Hsing-Chen Tsai; Xiaofei Wang; Craig Hooker; B Douglas Smith; Hetty E Carraway; James G Herman
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.